Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Hyperfine, Inc.NASDAQ: HYPR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$8.27M, compared with -$9.19M a year earlier. Trailing-twelve-month EBITDA was -$33.15M.
Context
- EBITDA amounted to 246.1% of revenue in FY2025, down 62.0 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$27.89M (+16.4%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.27M-58.5% QoQ
- Last fiscal yearDec 2025
- -$33.37M+16.0% YoY
- LTMMar 2026
- -$33.15M+15.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.0% | +2.1% | -7.9 pp |
| 1 year | +16.0% | +16.4% | +0.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.37M) USD
- Year-over-year change
- +16.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.37M) | +16.0% |
| FY2024 | 2024-12-31 | (39.71M) | +8.0% |
| FY2023 | 2023-12-31 | (43.18M) | +40.1% |
| FY2022 | 2022-12-31 | (72.15M) | -12.5% |
| FY2021 | 2021-12-31 | (64.13M) | — |
EBITDA vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 EBITDA of -$33.15M is the 3rd highest of the 7 companies compared; the peer median is -$42.97M.
- Its year-over-year change of +15.7% is the 2nd highest of 7, against a peer median of -10.9%.
- EBITDA amounts to 216.2% of revenue for HYPR, versus a peer median of 53.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.91M | -15.8% | -12.5% | 15.1% | |
| LTM Mar 2026 | -$26.64M | -14.1% | — | — | |
| LTM Mar 2026 | -$33.15M | +15.7% | — | 216.2% | |
| LTM Mar 2026 | -$37.72M | +25.1% | — | 52.1% | |
| LTM Mar 2026 | -$48.22M | +9.4% | — | 54.5% | |
IMAImageneBio Inc | LTM Mar 2026 | -$51.64M | -7.8% | — | — |
| FY2025 | -$54.58M | -270.2% | — | 85279.7% | |
| Peer median (excluding HYPR) | -$42.97M | -10.9% | -12.5% | 53.3% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.5M | 6.81M | 11.03M | 12.89M | 13.56M |
| Cost of Revenue | 2.66M | 5.91M | 6.28M | 7M | 6.81M |
| Gross Profit | (1.17M) | 907K | 4.76M | 5.89M | 6.75M |
| Gross Margin | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Research & Development | 25.84M | 28.16M | 22.49M | 22.5M | 17.45M |
| Selling, General & Admin | 37.86M | 46.63M | 30.38M | 26.62M | 26.39M |
| Operating Expenses | 63.7M | 74.78M | 52.87M | 49.12M | 43.84M |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 2.2M |
| EBITDA | (64.13M) | (72.15M) | (43.18M) | (39.71M) | (33.37M) |
| EBITDA Margin | -4286.4% | -1058.8% | -391.4% | -308.1% | -246.1% |
| Operating Income | (64.87M) | (73.87M) | (48.12M) | (43.22M) | (37.09M) |
| Operating Margin | -4336.1% | -1084.2% | -436.1% | -335.3% | -273.4% |
| Interest Income | 18K | 761K | 3.84M | 2.49M | 1.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17K | 710K | 3.88M | 2.5M | 1.51M |
| Income Before Tax | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Pre-Tax Margin | -4335.0% | -1073.7% | -401.0% | -315.9% | -262.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (64.83M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Net Margin | -4333.8% | -1073.7% | -401.0% | -315.9% | -262.3% |
| EPS (Basic) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| EPS (Diluted) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| Weighted Avg Shares | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
| Weighted Avg Shares (Diluted) | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.